Aim: This study aimed to determine the demographic, clinical, paraclinical, therapeutic, and evolutive characteristics of patients with bladder tumors who underwent transurethral resection of bladder tumors (TURBT) at a urology center in Douala, Cameroon. Patients and Methods: This was a retrospective study carried out from 2015 to 2019 on 32 patients with bladder tumors that were managed at the Centre medico-chirugical d’urologie in Douala, Cameroon. The relevant data were obtained from patients’ clinical records. Results: A total of 32 patients (25 men and 7 women) aged 29 - 75 years were included in this study. The mean age of the study participants was 58.63 ± 11.00 years. Among our study participants, there were 10 smokers (31.25%). Eight (25%) of them had occupational exposure while 2 (6.25%) had residential exposure to bladder cancer. Thirty (93.75%) presented with hematuria, 2 (6.25%) presented with recurrent urinary tract infections, and 1 (3.13%) presented with acute urinary colic. Nineteen (59.38%) of them were anemic, with 4 (12.5%) requiring blood transfusions. Twenty-seven (84.38%) of them had pedunculated tumors while 5 (15.62%) had sessile tumors. The tumor diameters ranged from 1 cm to 5 cm, with a mean diameter of 2.75 ± 1.22 cm. Complete resection was performed in 27 (84.38%) participants while partial resection was performed in 5 (15.62%) patients. The early single instillation of intravesical chemotherapy with mitomycin was performed in 8 (25%) patients. Only one (3.13%) patient had a postoperative complication, and seven (21.88%) patients experienced tumor recurrence and underwent a second TURBT. Two (6.25%) of the 32 patients died and 30 (93.75%) survived. Conclusion: TURBT is the gold standard method of managing bladder tumors. This procedure is at the same time diagnostic and therapeutic for tumors that do not invade the walls of the urinary bladder.
References
[1]
Richters, A., Aben, K.K.H. and Kiemeney, L.A.L.M. (2020) The Global Burden of Urinary Bladder Cancer: An Update. World Journal of Urology, 38, 1895-1904. https://doi.org/10.1007/s00345-019-02984-4
[2]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[3]
Janković, S. and Radosavljević V. (2007) Risk Factors for Bladder Cancer. Tumori Journal, 93, 4-12. https://doi.org/10.1177/030089160709300102
[4]
Farling, K.B. (2017) Bladder Cancer: Risk Factors, Diagnosis, and Management. The Nurse Practitioner, 42, 26-33. https://doi.org/10.1097/01.NPR.0000512251.61454.5c
[5]
Burger, M., Catto, J.W.F., Dalbagni, G., Grossman, H.B., Herr, H., Karakiewicz, P., et al. (2013) Epidemiology and Risk Factors of Urothelial Bladder Cancer. European Urology, 63, 234-241. https://doi.org/10.1016/j.eururo.2012.07.033
[6]
Jalloh, M., Cassell, A., Diallo, T., Gaye, O., Ndoye, M., Mbodji, M.M., et al. (2020) Is Schistosomiasis a Risk Factor for Bladder Cancer? Evidence-Based Facts. ournal of Tropical Medicine, 2020, Article ID: 8270810. https://doi.org/10.1155/2020/8270810
[7]
Shephard, E.A., Stapley, S., Neal, R.D., Rose, P., Walter, F.M. and Hamilton, W.T. (2012) Clinical Features of Bladder Cancer in Primary Care. British Journal of General Practice, 62, e598-e604. https://doi.org/10.3399/bjgp12X654560
[8]
DeGeorge, K.C., Holt, H.R. and Hodges, S.C. (2017) Bladder Cancer: Diagnosis and Treatment. American Family Physician, 96, 507-514.
[9]
Williamson, S.R., Montironi, R., Lopez-Beltran, A., MacLennan, G.T., Davidson, D.D. and Cheng, L. (2010) Diagnosis, Evaluation and Treatment of Carcinoma in Situ of the Urinary Bladder: The State of the Art. Critical Reviews in Oncology/Hematology, 76, 112-126. https://doi.org/10.1016/j.critrevonc.2010.01.005
[10]
Ohlmann, C.H. and Stöckle, M. (2010) Diagnostic Work-Up and Treatment of Bladder Cancer: Current Developments. Der Urologe, 49, 172-177. https://doi.org/10.1007/s00120-010-2377-6
[11]
Cicione, A., Cantiello, F. and Damiano, R. (2013) Cystoscopy in Non-Muscle-Invasive Bladder Cancer: When and How (Rigid or Flexible). Urologia Journal, 80, 11-15. https://doi.org/10.5301/RU.2013.10858
[12]
Kiss, B., Burkhard, F.C. and Thalmann, G.N. (2016) Open Radical Cystectomy: Still the Gold Standard for Muscle Invasive Bladder Cancer. World Journal of Urology, 34, 33-39. https://doi.org/10.1007/s00345-015-1729-7
[13]
Guillotreau, J., Gamé, X., Mouzin, M., Doumerc, N., Mallet, R., Sallusto, F., et al. (2009) Radical Cystectomy for Bladder Cancer: Morbidity of Laparoscopic versus Open Surgery. Journal of Urology, 181, 554-559. https://doi.org/10.1016/j.juro.2008.10.011
[14]
Furuse, H. and Ozono, S. (2010) Transurethral Resection of the Bladder Tumour (TURBT) for Non-Muscle Invasive Bladder Cancer: Basic Skills. International Journal of Urology, 17, 698-699. https://doi.org/10.1111/j.1442-2042.2010.02556.x
[15]
Cappellini, M.D. and Motta, I. (2015) Anemia in Clinical Practice-Definition and Classification: Does Hemoglobin Change With Aging? Seminars in Hematology, 52, 261-269. https://doi.org/10.1053/j.seminhematol.2015.07.006
[16]
Uchida, T., Ao, T., Ikeda, S., Yokoyama, E., Kadowaki, K., Shoji, K., et al. (1990) Clinical Statistics of the Bladder Tumor—Transurethral Resection Cases. Hinyokika Kiyo, 36, 1033-1038.
[17]
Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., Padala, S.A. and Barsouk, A. (2020) Epidemiology of Bladder Cancer. Medical Sciences, 8, Article No. 15. https://doi.org/10.3390/medsci8010015
[18]
Mancini, M., Righetto, M. and Baggio, G. (2020) Spotlight on Gender-Specific Disparities in Bladder Cancer. Urologia Journal, 87, 103-114. https://doi.org/10.1177/0391560319887327
[19]
Brennan, P., Bogillot, O., Cordier, S., Greiser, E., Schill, W., Vineis, P., et al. (2000) Cigarette Smoking and Bladder Cancer in Men: A Pooled Analysis of 11 Case-Control Studies. International Journal of Cancer, 86, 289-294. https://doi.org/10.1002/(SICI)1097-0215(20000415)86:2%3C289::AID-IJC21%3E3.0.CO;2-M
[20]
Pira, E., Piolatto, G., Negri, E., Romano, C., Boffetta, P., Lipworth, L., et al. (2010) Bladder Cancer Mortality of Workers Exposed to Aromatic Amines: A 58-Year Follow-Up. Journal of the National Cancer Institute, 102, 1096-1099. https://doi.org/10.1093/jnci/djq214
[21]
Zaghloul, M.S., Zaghloul, T.M., Bishr, M.K. and Baumann, B.C. (2020) Urinary Schistosomiasis and the Associated Bladder Cancer: Update. Journal of the Egyptian National Cancer Institute, 32, Article No. 44. https://doi.org/10.1186/s43046-020-00055-z
[22]
Abt, D., Bywater, M., Engeler, D.S. and Schmid, H.P. (2013) Therapeutic Options for Intractable Hematuria in Advanced Bladder Cancer. International Journal of Urology, 20, 651-660. https://doi.org/10.1111/iju.12113
[23]
Joynson, C.P., Sundar, S., Symonds, P. (2006) Anaemia Is Associated with Poor Overall Survival but Not with Inferior Local Control in Patients with Muscle Invasive Bladder Carcinoma Treated by Radical External Beam Radiotherapy. A Retrospective Study. Clinical Oncology, 18, 728-734. https://doi.org/10.1016/j.clon.2006.09.001
[24]
Ishikawa, O., Ohhigashi, H., Imaoka, S., Nakaizumi, A., Kitamura, T., Sasaki, Y., et al. (1989) The Difference in Malignancy between Pedunculated and Sessile Polypoid Lesions of the Gallbladder. American Journal of Gastroenterology, 84, 1386-1390.
[25]
Tanaka, M.F. and Sonpavde, G. (2011) Diagnosis and Management of Urothelial Carcinoma of the Bladder. Postgraduate Medicine, 123, 43-55. https://doi.org/10.3810/pgm.2011.05.2283
[26]
Pak, J.S., Haas, C.R., Anderson, C.B., DeCastro, G.J., Benson, M.C. and McKiernan, J.M. (2021) Survival and Oncologic Outcomes of Complete Transurethral Resection of Bladder Tumor Prior to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Urologic Oncology, 39, 787.e9-787.e15. https://doi.org/10.1016/j.urolonc.2021.03.025
[27]
Cesur, M., Erdem, A.F., Alici, H.A., Yapanoglu, T., Yuksek, M.S. and Aksoy, Y. (2008) The Role of Succinylcholine in the Prevention of the Obturator Nerve Reflex during Transurethral Resection of Bladder Tumors. Saudi Medical Journal, 29, 668-671.
[28]
Fukuhara, H., Kakizaki, H., Kaneko, H., Yamanobe, T., Nakayama, S., Horie, S., et al. (2017) Safety and Efficacy of Continuous Administration of Antithrombotic Drugs during Transurethral Resection of Bladder Tumors. Nihon Hinyokika Gakkai Zasshi, 108, 17-23. https://doi.org/10.5980/jpnjurol.108.17
[29]
Matulewicz, R.S., Sharma, V., McGuire, B.B., Oberlin, D.T., Perry, K.T. and Nadler, R.B. (2015) The Effect of Surgical Duration of Transurethral Resection of Bladder Tumors on Postoperative Complications: An Analysis of ACS NSQIP Data. Urologic Oncology, 33, 338.e19-338.e24. https://doi.org/10.1016/j.urolonc.2015.05.011
[30]
Bangash, M., Ather, M.H., Khan, N., Mohammad, S. and Uddin, Z. (2020) Comparison of Recurrence Rate between “EN BLOC” Resection 0f Bladder Tumour and Conventional Technique for Non-Muscle Invasive Bladder Cancer. Journal of Ayub Medical College Abbottabad, 32, 435-440.
[31]
Fradet, V., Mauermann, J., Kassouf, W., Rendon, R., Jacobsen, N., Fairey, A., et al. (2014) Risk Factors for Bladder Cancer Recurrence after Nephroureterectomy for Upper Tract Urothelial Tumors: Results from the Canadian Upper Tract Collaboration. Urologic Oncology, 32, 839-845. https://doi.org/10.1016/j.urolonc.2014.04.006
[32]
Bansal, A., Sankhwar, S., Goel, A., Kumar, M., Purkait, B. and Aeron, R. (2016) Grading of Complications of Transurethral Resection of Bladder Tumor Using Clavien-Dindo Classification System. Indian Journal of Urology, 32, 232-237. https://doi.org/10.4103/0970-1591.185104
[33]
Boustead, G.B., Fowler, S., Swamy, R., Kocklebergh, R. and Hounsome, L. (2014) Section of Oncology, BAUS. Stage, Grade and Pathological Characteristics of Bladder Cancer in the UK: British Association of Urological Surgeons (BAUS) Urological Tumour Registry. BJU International, 113, 924-930. https://doi.org/10.1111/bju.12468
